Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.

The present invention relates to a pad printing method for producing an administration form for a pharmaceutical active agent, wherein the method comprises providing a substrate of the administration form and transferring the active agent by means of a pad from a cliché onto the substrate, wherein the area of the cliché is larger than the active-agent-containing area printed onto the substrate. This method is especially suitable for producing transdermal therapeutic systems with volatile active agents. The present invention also relates to arrangements by means of which a method of this kind can be implemented.

A transdermal absorption-type patch (10) includes: a support material (1) and an adhesive layer (2) laminated on the support material (1). The adhesive layer (2) includes: a solid composite material (2a), the solid composite material (2a) being an active ingredient with a molecular weight of 800 or greater enclosed by a surfactant; an oil phase; and an adhesive agent, the adhesive agent containing an acrylic elastomer. The content of the acrylic elastomer is 30% to 70% by mass based on the total mass of the acrylic elastomer and the oil phase. The composite material (2a) forms a solid-in-oil type particle dispersed in the oil phase.

The present disclosure, for example, can include a laminated type patch A, comprising a release layer 1, a drug layer 2, a drug support layer 3 having elasticity, an adhesive layer 4, and an adhesive support layer 5 laminated in this order, wherein the outer edges of the release layer, the adhesive layer, and the adhesive support layer are all outside the outer edges of both the drug layer and the drug support layer; wherein the portion surrounded by the outer edges of the drug layer and the drug support layer, and the inner sides of the release layer and the adhesive layer has a space; and wherein the cross-sectional area of the space is 0.3 mm2 or more, at least when cut along the longitudinal centerline and the transverse centerline on the plane surfaces of the drug layer and the drug support layer.

A patch for at least partially reducing at least one of pain, swelling, inflammation and irritation in at least one body part of a user is provided. The patch includes at least one cloth layer having the propolis composition embedded therein. The patch includes a first plastic layer disposed immediately against a first side of the at least one cloth layer, and a second plastic layer disposed immediately against a second side of the at least one cloth layer opposite the first side, such that the at least one cloth layer is sandwiched between the first and second plastic layers. The propolis composition is configured to at least partially reduce at least one of perceived pain, swelling, inflammation and irritation when the patch is applied to the at least one body part. Related methods of use and/or manufacture for such a patch are also provided.

Hemostatic compositions including a combination of more than one hemostatic agent, and devices coated or impregnated therewith, have been developed. Nanotechnology yields hemostatic agents with large surface areas thereof, thereby increasing the hemostatic properties of the device to which they are applied. By combining more than one hemostatic agent and utilizing one or more different nanotechnology approaches to enhance the surface areas thereof, the capability of the dressing to stop bleeding is improved via more than one mechanism, and thus provides better hemostasis.

Hemostatic compositions including a combination of more than one hemostatic agent, and devices coated or impregnated therewith, have been developed. Nanotechnology yields hemostatic agents with large surface areas thereof, thereby increasing the hemostatic properties of the device to which they are applied. By combining more than one hemostatic agent and utilizing one or more different nanotechnology approaches to enhance the surface areas thereof, the capability of the dressing to stop bleeding is improved via more than one mechanism, and thus provides better hemostasis.

In another example, a bioresorbable implant for use in a nasal region includes one or more bioresorbable polymers, and a pharmaceutical composition coupled to the one or more bioresorbable polymers. A release rate of the pharmaceutical composition is related to a degradation rate of the one or more bioresorbable polymers.

a film composite for manufacturing a package for planar carriers of pharmaceutical active substances, for example transdermal patches, encompassing, in a direction from the outer side of the film composite toward its inner side: a metal layer; an acrylic-acid-containing joining layer; a polyethylene layer; and a COC layer made of cycloolefin copolymer, a side of the COC layer which faces away from the metal layer being an exposed surface of the film composite, wherein provision is made that the polyethylene layer encompasses metallocene polyethylene.

A pharmaceutical active-containing transmucosal delivery device comprises a polymer film comprising a polymer matrix, wherein the film has a pH in the range of about 4 to about 9, and a pharmaceutical active composition disposed on a surface of the polymer film. The composition comprises at least one pharmaceutical active ingredient in the form of particles, and wherein the particles have an average particle size of about 100 nm to about 5 microns, an anti-crystallization agent, and a pH adjusting agent, wherein the concentration of the pharmaceutical active ingredient is at least 20% w/w relative to the total weight of the pharmaceutical active composition. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 30 minutes and is substantially mucoadhesive to a mucosa surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek.